小儿哮喘诊断及防治进展

www.yongyao.net　　2009-7-10 17:02:14　　来源：　　责任编辑：

分享到：

参　考　文　献
1.陈育智,李元,刘世英,李大维,龚明敏,等1北京地区4 万儿童哮喘患病情况调查1 北京医学,1995, 17: 1 - 4. 1
2.陈育智,陈再历,曹玲,林良明, , 2000年北京城市儿童哮喘患病情况调查分析. 北京医学, 2002, 24:(3) 173 - 761
3.曹玲,陈育智,陈再历,等. 中国儿童哮喘治疗现状及与10年前比较临床儿科杂志. 2003, 21: ( 11)
704 - 7061
4.李昌崇,张维溪,儿童哮喘诊断治疗中存在问题探讨. 临床儿科杂志2005, 23: 1 15 - 171
5.李昌崇,黄达枢,婴幼儿哮喘的临床特征及其与喘息性疾病相互关系的探讨. 临床儿科杂志. 1997,
15 (2) : 96 - 971
6.National institute of health, national heart, lung, andblood instituteGlobalinitiative for asthma. 2002, 74 -761
7. The childhood asthma management p rogram researchgronp. Long term effectsofbndesonide or nedocromilin children With asthma. N Engl J Med, 2000, 343:1054 - 10631
8.陈育智,曹玲,刘世英,等1吸入二丙倍氯米松治疗婴幼儿哮喘的疗效观察1中国实用儿科杂志,2002, 15 (10) 6041
9. Long～ term effects of budesonide or nedocromil inchildren With asthma. The Childhood Asthma Man2agement Program Research Group. N Engl J Med,2000, 343: 1054 - 10, 63.
10.Agertoft L, Pedersen S. Effect of long - term treat2ment W ith inhaled budesonide onadult height inchildren W ith asthma. N Engl J Med, 2000, 343:1064 - 1069.
11. Greening AP, Ind PW, Northfiel dM, et al. Addedsalmeterol versus higherdosecorticosteroid in asthmaPatientsWith symp toms on existing inhaled cortico2steroid. Lancet, 1994, 344: 219 - 224.
12. Shrewburys, Pyke S, Britton M. Meta - analysis ofincreased dose of inhaledsteroidor addition of salme2terol in symp tomatic asthma [M IAS～MA ]. BMJ,2000, 320: 1368 - 1393.
13. BarnesP J. Scientific rational for inhaled combina2tion therapy with long～actingβ2 agonists and certi2costeroids. Eur Resp ir J, 2002, 19: 182 - 191.
14. Bateman ED,Bousquet J , Braunstein GL. is over allasthma control being achieved? A hypothesis～gen2rating study. Eur Resp ir J , 2001.
15. StormsW,Michele TM, KnorrB, et al. Clinical safe2ty and tolerability of montelukast, a leukotriene re2cep tor antagonist, in controlled clinical trials in pa2tiens aged > or = 6 years. Clin Exp Allergy, 2001,31: 77 - 873.
16.Malmstrom K, Rodriguez2Gomez G, Guerra J, et al.Oralmontelukast, inhaled beclomethasone, and p la2cebo for chronic asthma. A randomized, controlledtrialMontelukast/Beclomethasone Study Group. AnnInternMed, 1999, 130: 487 - 495.
17. StempelDA, Stanford RH,McLaughhlin T, et al. Sixmonth claims analysis demonstes thatmontelukast isassociated with a significantly larger increase inasth2ma care costs than fluticasone p rop ionate. Am J Re2sp ir Crit CareMed, 2000, 161: A 407.
18.William O C, Cookson M,MoffattM F. Asthma: Anep idemic in the absence of infection? Science,1997, 275 (5296) : 41 - 42.
19. Shirakawa T, Enomoto T, Shimazu S, et al. The in2verse association between tuberculin response andatop ic disorder. Science, 1997, 275 ( 5296 ) : 77 -79.
20.商艳,胡振林,李强,等1卡介苗及其衍生物与支气管哮喘的治疗. 中华结核和呼吸杂志, 2003, 26
(3) : 169 - 171.
21.陈坤华,赵晓东,高武红,等1卡介苗多糖核酸治疗哮喘儿前后PPD反应与Th1 /Th2的相关性. 实
用儿科临床杂志, 2001, 16 (2) : 751
22. Bousques J, Lockey R,Malling IIJ. Allergen immu2notherapy: therapeutic cassines for allergic disease.AwHo. Position paper. J Allerg clinLmmuno, 1998,102 (4p t1) : 558.
23. Leck ieMJ, ten B rinke A, Khan J,D iam an t Z,O’Conno rBJ,Walls CM, e ta. effects of an interleukin5 blocking monoclonal antbody on eosinophilis, air2way responsiveness and late asthmatic response Lan2cet 2000, 356: 214 - 428.
24. B ryan SA,O’Conno r BJ ,Matti S, L eck ieMJ , Ka2naba r V, Khan J , e t a l. effects of recombinant hu2man interleukin～12 on eosinophilis, airway and the late asthmatic response Lacent 2000, 356: 21 49 -53.
25.Vigno la AM, Hum be rtM,Bousque t J ,Bou le tLP,Hedgecock S,B loggM, etal. Efficacy and tolerablity of anti～immunoglobulin E therapy with Omalizum2 abin patients with concomitant allergic asthma and persistene allergic rhinitis: SOLAR. Allergy 2004,
59: 709 - 17.
26.Ayre s JG, Higgin s B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti～ immu2 noglobin E therapywith omalizumab in patientswith poorly controlled (moderate to severe asthma) aller2 gic asthma A llergy 2004, 59: 701 - 8.
27. B ritish guide line on the management of asthma.Thorax 2003, 58 ( supp ll) : il294.
28. Johnston SL, Pattttenmore PK, Sanderson G, et al.The relationship between upper Resp iratory infec2tions and hosp ital admissions for asthma a time trend anylysis. Am J Resp ir Crit CareMed, 1996,154 654 - 660.
29.Daian CM, Wolff AH, B ieloryL, et al. Serologic markers for atyp ical organismslnasthma. Allergy Asthma Pta, 2000, 21 (2) : 107.
30. Passalacqaa G, Cip rand G, Canonica G W. United airways disease: therapeutic aspects. Thorax, 2000,55 ( supp12) : 26.
31.Mace S E. Asthma therapy in the observation unitemergancy medicine clinics of south America,2001, 19 (1) : 169.
32. Campball GD, File TM, Lillington, et al. trends inresp iratory medicine: asthmaand allergy. J Resp irDis, 1999, 20 (10) : 676.
33. Shiekh S, Stephen T, Howell l, et al Gastroesophage2al reflux in infants with wheezing, pediatric pul2monol 1999, 28 (3) : 181 - 186.
34. Powell RM, Hamilton LM, Holgate ST, DaviesDE,Holloway JW. ADAM33: a novel therapeutic targetfor asthma. ExpertOp in Ther Targets 2003, 7: 485 -94.